Adoption for policy for implementation of NFRA circular
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported audited FY2026 results with revenue of Rs. 7,717 crore (up 16.6% from Rs. 6,615 crore in FY2025), but profit after tax declined 13% to Rs. 410.5 crore from Rs. 473.5 crore. EBITDA margin also compressed to 8.56% from 10.64% in the prior year. The Board recommended a dividend of Rs. 1.50 per share (30% payout) subject to shareholder approval at the AGM on 12th August 2026. Nine promoter group shareholders holding ~0.95% stake have requested re-classification from 'Promoter Group' to 'Public' category. The company also adopted a new NFRA (National Financial Reporting Authority) circular policy. Key appointments include a new General Manager-Quality and re-appointment of two directors retiring by rotation.
The revenue growth is positive but declining margins and PAT signal operational cost pressures. Promoter group re-classification requests may indicate reduced promoter stake, which could be a minor bearish signal. The dividend recommendation is encouraging for retail shareholders.